PrairieGold Venture Partners
PrairieGold Venture Partners is a venture capital firm located in Sioux Falls, South Dakota, that focuses on early-stage investments. The firm specializes in sectors such as life sciences, green technology, information technology, and alternative energy. PrairieGold typically invests between $0.25 million and $2 million in companies, with transaction sizes ranging from $0.25 million to $10 million. The firm aims to support companies in the Midwest region and often seeks a board seat in its portfolio companies to provide guidance and oversight.
https://app.dealroom.co/companies/***
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in South Dakota
Chronix Biomedical
Venture Round in 2012
Chronix Biomedical, Inc. is a molecular diagnostics company specializing in the development of laboratory-developed blood tests, known as liquid biopsy tests, for cancer and organ transplant monitoring. Founded in 1997 and headquartered in San Jose, California, the company has established laboratories in Brookings, South Dakota, and Göttingen, Germany. Chronix's products include the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, designed to detect organ rejection by quantifying transplant-specific DNA in plasma. The company employs proprietary technology to analyze circulating nucleic acids, allowing for the diagnosis and management of chronic diseases and cancer. Chronix aims to partner with various organizations to expand its DNA-based assays, which have the potential to improve the management of a wide range of cancers and other health conditions.
Chronix Biomedical
Series B in 2008
Chronix Biomedical, Inc. is a molecular diagnostics company specializing in the development of laboratory-developed blood tests, known as liquid biopsy tests, for cancer and organ transplant monitoring. Founded in 1997 and headquartered in San Jose, California, the company has established laboratories in Brookings, South Dakota, and Göttingen, Germany. Chronix's products include the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, designed to detect organ rejection by quantifying transplant-specific DNA in plasma. The company employs proprietary technology to analyze circulating nucleic acids, allowing for the diagnosis and management of chronic diseases and cancer. Chronix aims to partner with various organizations to expand its DNA-based assays, which have the potential to improve the management of a wide range of cancers and other health conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.